US6047491013
© BusinessWire
11.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,820 shares of common stock and 7,840 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with B...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).
Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum di...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
25.11.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
8th Annual Evercore HealthCONx Conference on T...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
11.11.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,500 shares of common stock and 27,950 restricted stock units (“RSUs”) to 11 new employees under Mirum’s 2020 Inducement Pla...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washi...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update.
“Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore th...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
2025 Stifel Healthcare Conference
Company p...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress.
Conference call details:
Tuesday November 4th, 2025
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:...
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 45,800 shares of common stock and 22,850 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,820 shares of common stock and 5,390 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.08.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Citi Biopharma Back-to-School Summit on Wedne...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress.
Conference call details:
Wednesday, August 6th, 2025
4:30 p.m. ET / 1:30 p.m. PT
D...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 14,460 shares of common stock and 7,220 restricted stock units (“RSUs”) to two new employees under Mirum’s 2020 Inducement Plan. T...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Plan....
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies.
Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., wh...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
3rd Annual H.C. Wainwright BioConnect Investor...
Themefolio
Profiler
Peergroup
© BusinessWire
10.05.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan....
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
TKOMF
LISTED
OTC
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC).
“The extended VANTAGE...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter 2025 and provided a business update.
“It’s been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline,” said Chris Peetz, chief executive officer of Mirum. “We’re pleased with the FDA’s approval of LIM...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress.
Conference call details:
Wednesday, May 7, 2025
4:30 p.m. ET / 1:30 p.m. PT
Dial...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be held in San Diego, May 3-6, 2025. The European Association for the Study of the Liver (EASL) will take place May 7-10 in Amsterdam, the Netherlands. The 57th European Society for Paediatric...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
TKOMF
LISTED
OTC
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
“The approval of LIVMARLI in tabl...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 39,740 shares of common stock and 19,830 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Pla...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
TKOMF
LISTED
OTC
LIVMARLI Now Approved in Japan for ALGS and PFIC
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intr...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan....
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update.
“2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,” said Chris Peetz, chief executive officer of Mirum. “We continue to expan...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
TKOMF
LISTED
OTC
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI™ (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). CTEXLI is the first and only treatment approved for this rare, progressive and debilitating disease.
The approval...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26, 2025. Mirum will also host a conference call to discuss the fourth quarter and year-end 2024 financial results and recent corporate progress.
Conference call details:
Wednesday, February 26,...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 49,600 shares of common stock and 24,800 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Pla...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook.
“2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones,” said Ch...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,900 shares of common stock and 26,950 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15,...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 48,400 shares of common stock and 24,200 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California.
Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are ava...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update.
“The Mirum team executed across all aspects of the business in the third quarter with growth across all three commercial medicines highlighted by acceleration of LIVMARLI PFIC sales,” said Chris Peetz, chief exec...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Stifel 2024 Healthcare Conference on Tuesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress.
Conference call details:
Tuesday, November 12, 2024
8:30 a.m. ET / 5:30 a.m. PT
Dia...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS)...
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,100 shares of common stock and 17,050 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Pl...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2024
TKOMF
LISTED
OTC
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC). The regulatory designation is based on the positive interim analysis of the Phase...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,700 shares of common stock and 9,850 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
10.08.2024
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 59,000 shares of common stock and 29,500 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Pla...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
